Cosmo Pharmaceuticals NV
SSIX:COPNCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Giovanni di Napoli
- Full Time Employees
- 325
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Riverside 2 Dublin DU Ireland D02 KV60
- IPO Date
- May 18, 2016
- Website
- cosmopharma.com
- Similar Companies
- Business
- Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of innovative products primarily in gastroenterology and dermatology. Its core product portfolio includes Lialda/Mezavant/Mesavancol and Uceris/Cortiment, oral tablet formulations for ulcerative colitis; GI Genius, an artificial intelligence-based system for colorectal polyp detection during colonoscopy; Eleview, an injectable composition used in gastrointestinal endoscopic procedures; Aemcolo/Relafalk for treatment of traveler's diarrhea and related conditions; Winlevi, an androgen receptor inhibitor for acne vulgaris; as well as additional pipeline products like Clascoterone for androgenetic alopecia, Rifamycin for irritable bowel syndrome with diarrhea, ByFavo (Remimazolam) for procedural sedation, and Qolotag, a single-use enema formulation. The company also leverages proprietary galenic multi-matrix technology (MMX) for controlled drug release and targets markets globally, operating primarily out of its headquarters in Dublin, Ireland, with a founding year of 1997. Recent major company developments include the European Commission's market authorization of Winlevi (clascoterone cream) in partnership with Glenmark Pharmaceuticals, enhancing Cosmo's position in dermatology. The company renewed a multi-year manufacturing and supply agreement with Takeda for the production of Mesalazine MMX (marketed as Lialda in the U.S. and Mezavant in Europe), underpinning stable revenues. Cosmo executed significant growth in its AI-driven GI Genius system with recurring revenues increasing 128% year-over-year, and Winlevi sales rising 23%. It implemented strategic expansions focusing on AI-enhanced healthcare, dermatology innovation, and pharmaceutical manufacturing scale-up aligned with its Vision 2030 strategy. Additionally, Cosmo is advancing its late-stage clinical pipeline with key Phase III trial results pending for treatments targeting male androgenetic alopecia, supporting future market expansion plans in dermatology and gastrointestinal diseases. Cosmo operates within the specialty pharmaceuticals industry, serving healthcare providers, hospitals, and patients worldwide with a focus on innovative therapeutics and diagnostic innovations in gastrointestinal and dermatological disorders. The company leverages strategic partnerships and technology investments including artificial intelligence to augment its product offerings and pipeline development. It maintains a strong financial position with stable recurring revenues, significant cash reserves, and an emphasis on growth through clinical advancement and geographic expansion into markets such as Europe, the United States, and emerging regions. Overall, Cosmo Pharmaceuticals combines proprietary drug formulation technologies, AI-powered diagnostic tools, and a diversified specialty pharmaceutical product range to address unmet medical needs in gastroenterology and dermatology, solidifying its competitive stance and growth prospects as of late 2025. This description reflects Cosmo Pharmaceuticals N.V.'s detailed product offerings, geographic reach, founding and headquarters information, and major corporate developments through 2025.
Company News
Cosmo Announces SIX Ticker Symbol Change to "CMHC"
Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Voting Results of Cosmo's 2026 AGM
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
Cosmo Announces Breakthrough Phase III Topline Results from Scalp 1 and Scalp 2 for Clascoterone 5% Solution in Male Hair Loss, Showing up to 539% Relative Improvement in Target-Area Hair Count vs Placebo; US and EU Submissions are Underway
Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi®
Winlevi(R) Receives Regulatory Approval in Brazil - Expanding Global Access to a Breakthrough Acne Treatment